SCHEMBL24019173

SCHEMBL24019173

Cc1ccc(Nc2cc(CN(C)Cc3cccc(C#N)c3)nc(N)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.47
CSNK1A1 P48729 1/20 0.39
CSNK1D P48730 1/20 0.39
GSK3B P49841 1/20 0.39
CSNK1G2 P78368 1/20 0.39
AGPAT2 O15120 2/20 0.39
HTT P42858 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ABCG2 Q9UNQ0 4/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 1/20 0.37
MCHR1 Q99705 1/20 0.37
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TLR8 Q9NR97 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21530446 0.91 AGPAT2 (0.42) SLC2A1AGPAT2NPC1RAB9AABCG2
SCHEMBL20355776 0.89 AGPAT2 (0.43) SLC2A1CSNK1A1CSNK1DGSK3BCSNK1G2
SCHEMBL20338993 0.87 HRH4 (0.42) AGPAT2HTTNPC1RAB9ACYP1A2
SCHEMBL20338961 0.86 ABCG2 (0.47) SLC2A1AGPAT2SMN1; SMN2ABCG2CYP1A2
SCHEMBL20339002 0.85 ABCG2 (0.47) AGPAT2ABCG2CYP1A2CYP2D6ABCB1
SCHEMBL20339039 0.85 CYP1A2 (0.49) AGPAT2HTTNPC1RAB9ASMN1; SMN2
SCHEMBL20355763 0.85 ROCK1 (0.46) AGPAT2NPC1RAB9AABCG2MCHR1
SCHEMBL20355109 0.85 MCHR1 (0.52) AGPAT2NPC1RAB9ACYP1A2CYP2D6
SCHEMBL20340282 0.84 RAB9A (0.44) AGPAT2HTTNPC1RAB9ASMN1; SMN2
SCHEMBL20355770 0.83 RAB9A (0.47) SLC2A1RAB9ASMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2022-05-05 US disclosed
US-11174242-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2021-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE GBA1, GBA2, GAA SLC2A1 2317/4885CSNK1A1 1466/4885CSNK1D 1580/4885
US-11174242-B2 Heteroaryl compounds and their use GBA1, GBA2, GAA SLC2A1 2317/4885CSNK1A1 1466/4885CSNK1D 1580/4885
US-11739072-B2 Heteroaryl compounds and their use GBA1, GBA2, GAA SLC2A1 2317/4885CSNK1A1 1466/4885CSNK1D 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.